Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shanghai Pharmaceuticals Holding Co Ltd
Accrued Liabilities
Shanghai Pharmaceuticals Holding Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Accrued Liabilities
¥1.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
17%
|
CAGR 10-Years
14%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Accrued Liabilities
¥29.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
18%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Accrued Liabilities
¥534m
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
15%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Accrued Liabilities
¥92.9m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Accrued Liabilities
¥238.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
16%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Accrued Liabilities
¥270.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
7%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
Glance View
Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.
See Also
What is Shanghai Pharmaceuticals Holding Co Ltd's Accrued Liabilities?
Accrued Liabilities
1.8B
CNY
Based on the financial report for Sep 30, 2025, Shanghai Pharmaceuticals Holding Co Ltd's Accrued Liabilities amounts to 1.8B CNY.
What is Shanghai Pharmaceuticals Holding Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
14%
Over the last year, the Accrued Liabilities growth was 15%. The average annual Accrued Liabilities growth rates for Shanghai Pharmaceuticals Holding Co Ltd have been 15% over the past three years , 17% over the past five years , and 14% over the past ten years .